TetraLogic Pharmaceuticals Corporation – OTC:TLOG
TetraLogic Pharmaceuticals stock price today
TetraLogic Pharmaceuticals stock price monthly change
TetraLogic Pharmaceuticals stock price quarterly change
TetraLogic Pharmaceuticals stock price yearly change
TetraLogic Pharmaceuticals key metrics
Market Cap | 458.72K |
Enterprise value | 24.92M |
P/E | -0.01 |
EV/Sales | N/A |
EV/EBITDA | -0.69 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.83 |
Revenue | N/A |
EBITDA | -23.42M |
Income | -45.75M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTetraLogic Pharmaceuticals stock price history
TetraLogic Pharmaceuticals stock forecast
TetraLogic Pharmaceuticals financial statements
| Dec 2015 | 0 | -15.91M | |
|---|---|---|---|
| Mar 2016 | 0 | -12.74M | |
| Jun 2016 | 0 | -8.46M | |
| Sep 2016 | 0 | -8.63M |
| Dec 2015 | 64021390 | 69.96M | 109.28% |
|---|---|---|---|
| Mar 2016 | 57599987 | 73.66M | 127.89% |
| Jun 2016 | 51056589 | 73.31M | 143.59% |
| Sep 2016 | 42787553 | 73.72M | 172.31% |
| Dec 2015 | -9.19M | 8.51M | 0 |
|---|---|---|---|
| Mar 2016 | -6.03M | 5.26M | 0 |
| Jun 2016 | -5.86M | 0 | 0 |
| Sep 2016 | -2.79M | 0 | 0 |
TetraLogic Pharmaceuticals alternative data
| Aug 2023 | 29 |
|---|---|
| Sep 2023 | 29 |
| Oct 2023 | 29 |
| Nov 2023 | 29 |
| Dec 2023 | 29 |
| Jan 2024 | 29 |
| Feb 2024 | 29 |
| Mar 2024 | 29 |
| Apr 2024 | 29 |
| May 2024 | 29 |
| Jun 2024 | 29 |
| Jul 2024 | 29 |
TetraLogic Pharmaceuticals other data
-
What's the price of TetraLogic Pharmaceuticals stock today?
One share of TetraLogic Pharmaceuticals stock can currently be purchased for approximately $0.
-
When is TetraLogic Pharmaceuticals's next earnings date?
Unfortunately, TetraLogic Pharmaceuticals's (TLOG) next earnings date is currently unknown.
-
Does TetraLogic Pharmaceuticals pay dividends?
No, TetraLogic Pharmaceuticals does not pay dividends.
-
How much money does TetraLogic Pharmaceuticals make?
TetraLogic Pharmaceuticals has a market capitalization of 458.72K.
-
What is TetraLogic Pharmaceuticals's stock symbol?
TetraLogic Pharmaceuticals Corporation is traded on the OTC under the ticker symbol "TLOG".
-
What is TetraLogic Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of TetraLogic Pharmaceuticals?
Shares of TetraLogic Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does TetraLogic Pharmaceuticals have?
As Jul 2024, TetraLogic Pharmaceuticals employs 29 workers.
-
When TetraLogic Pharmaceuticals went public?
TetraLogic Pharmaceuticals Corporation is publicly traded company for more then 11 years since IPO on 12 Dec 2013.
-
What is TetraLogic Pharmaceuticals's official website?
The official website for TetraLogic Pharmaceuticals is tetralogicpharma.com.
-
Where are TetraLogic Pharmaceuticals's headquarters?
TetraLogic Pharmaceuticals is headquartered at 343 Phoenixville Pike, Malvern, PA.
-
How can i contact TetraLogic Pharmaceuticals?
TetraLogic Pharmaceuticals's mailing address is 343 Phoenixville Pike, Malvern, PA and company can be reached via phone at +61 8899900.
TetraLogic Pharmaceuticals company profile:
TetraLogic Pharmaceuticals Corporation
tetralogicpharma.comOTC
29
Biotechnology
Healthcare
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Malvern, PA 19355
:
ISIN: US88165U1097
CUSIP: 88165U109
